BioSpace News Archive

Enpro Inc. announced that it has entered into a definitive agreement to acquire Advanced Micro Instruments, Inc., a leading provider of highly-engineered, application-specific analyzers and sensing technologies that monitor critical parameters to maintain infrastructure integrity, enable process efficiency, enhance safety, and facilitate the clean energy transition.

Microbot Medical Inc. announces the successful completion of its GLP pivotal pre-clinical study, done under the guidelines of FDA-required levels of planning, controlling, monitoring, and reporting, using a porcine model.

MiMedx Group, Inc. announced that its outstanding 95,000 shares of Series B Convertible Preferred Stock, together with any accrued dividends, were automatically converted into shares of the Company’s Common Stock on December 22, 2023, in accordance with the Preferred Stock terms set forth in the Company’s Articles of Incorporation.

Hi-Tech Pharmaceuticals, a leading manufacturer of cutting-edge dietary supplements and weight management supplements, is proud to announce the launch of its latest product, SLIMAGLUTIDE®.

HR Pharmaceuticals, Inc. announced that they have entered into an Exclusive Commercial Agreement with Poiesis Medical LLC, under which HRP will license Poiesis’s Dual Balloon Catheter.

Boston Scientific Corporation has initiated the AVANT GUARD clinical trial to evaluate the safety and effectiveness of the FARAPULSE™ Pulsed Field Ablation System* as a first-line treatment for persistent atrial fibrillation, the only trial to study the use of PFA as frontline therapy in patients with this form of AF.

Titan Pharmaceuticals, Inc. announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company’s common stock, which will be effective following the filing of an amendment to the Company’s Amended and Restated Certificate of Incorporation.

Ascendis Pharma A/S announced that Jan Mikkelsen, President & Chief Executive Officer, Scott Smith, Executive Vice President & Chief Financial Officer, and Kennett Sprogøe, Ph.D., Executive Vice President, Head of Research & Product Development, will participate in the 42nd Annual J.P. Morgan Healthcare Conference.

Teva Pharmaceutical Industries Ltd. announced that Richard Francis, Teva’s President and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024.

Iridex Corporation, a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, announced all five Medicare Administrative Contractors retired their local coverage determinations that were scheduled to take effect on January 29, 2024.